銀保監會批準平安人壽保險於方正控股(00418.HK)股東股權投資申請
方正控股(00418.HK)公佈,中國銀保監會已批準中國平安(02318.HK)非全資擁有附屬公司平安人壽保險於新方正集團的重大股權投資之申請。目前,與平安人壽保險投資於新方正集團有關的監管機構要求的現階段的所有批準均已獲得。
新方正集團之下屬業務平臺公司的註冊成立已完成,其全部六間下屬業務平臺公司已經成立,將會受讓北大方正等五家公司可適用的股權類資產債券類資產和其他資產,以及重整投資者將會於其後受新方正集團股權。北大方正間接持有公司的股權將由重整投資者間接持有。公司的股權轉讓至新方正集團之下屬業務平臺公司,仍須滿足某些先決條件,而公司未知該轉讓的確切時間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.